AVROBIO, Inc. (AVRO) Financial Statements (2023 and earlier)
Company Profile
Business Address |
100 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
---|---|---|---|---|---|---|
ASSETS | ||||||
Current Assets | ||||||
Cash, cash equivalents, and short-term investments | 189,567 | 259,682 | 187,043 | 126,302 | ||
Cash and cash equivalents | 189,567 | 259,682 | 187,043 | 126,302 | ||
Receivables | 4 | 224 | 220 | |||
Prepaid expense | 112 | 973 | 983 | 397 | ||
Other current assets | 1,698 | 271 | 620 | 795 | ||
Other undisclosed current assets | 7,768 | 6,312 | 6,831 | 2,306 | ||
Total current assets: | 199,145 | 267,242 | 195,701 | 130,020 | ||
Noncurrent Assets | ||||||
Property, plant and equipment | 4,126 | 3,064 | 3,696 | 2,634 | ||
Restricted cash and investments | 492 | 492 | ||||
Other noncurrent assets | 74 | 436 | 1,117 | 825 | ||
Total noncurrent assets: | 4,692 | 3,992 | 4,813 | 3,459 | ||
TOTAL ASSETS: | 203,837 | 271,234 | 200,514 | 133,479 | ||
LIABILITIES AND EQUITY | ||||||
Liabilities | ||||||
Current Liabilities | ||||||
Accounts payable and accrued liabilities | 19,124 | 16,375 | 14,017 | 10,606 | ||
Accounts payable | 3,486 | 2,682 | 3,949 | 2,784 | ||
Accrued liabilities | 15,638 | 13,693 | 10,068 | 7,822 | ||
Deferred rent credit | 262 | 239 | ||||
Total current liabilities: | 19,386 | 16,614 | 14,017 | 10,606 | ||
Noncurrent Liabilities | ||||||
Long-term debt and lease obligation | 14,945 | |||||
Long-term debt, excluding current maturities | 14,945 | |||||
Liabilities, other than long-term debt | 30 | 276 | 484 | 689 | ||
Deferred rent credit | 30 | 276 | 484 | 689 | ||
Total noncurrent liabilities: | 14,975 | 276 | 484 | 689 | ||
Total liabilities: | 34,361 | 16,890 | 14,501 | 11,295 | ||
Stockholders' equity | ||||||
Stockholders' equity attributable to parent | 169,476 | 254,344 | 186,013 | 122,184 | ||
Common stock | 4 | 4 | 3 | 2 | ||
Additional paid in capital | 553,014 | 518,756 | 330,714 | 193,921 | ||
Accumulated deficit | (383,542) | (264,416) | (144,704) | (71,739) | ||
Total stockholders' equity: | 169,476 | 254,344 | 186,013 | 122,184 | ||
TOTAL LIABILITIES AND EQUITY: | 203,837 | 271,234 | 200,514 | 133,479 |
Income Statement (P&L) ($ in thousands) Annual | Quarterly
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
---|---|---|---|---|---|
Operating expenses | (118,841) | (120,228) | (75,809) | (46,243) | |
Operating loss: | (118,841) | (120,228) | (75,809) | (46,243) | |
Nonoperating income (expense) | (285) | 516 | 2,844 | (118) | |
Investment income, nonoperating | (224) | 719 | 2,934 | 97 | |
Other nonoperating expense | (61) | (203) | (90) | (53) | |
Net loss attributable to parent: | (119,126) | (119,712) | (72,965) | (46,361) | |
Preferred stock dividends and other adjustments | (2,243) | ||||
Net loss available to common stockholders, diluted: | (119,126) | (119,712) | (72,965) | (48,604) |
Comprehensive Income ($ in thousands)Annual | Quarterly
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
---|---|---|---|---|---|
Net loss: | (119,126) | (119,712) | (72,965) | (46,361) | |
Comprehensive loss, net of tax, attributable to parent: | (119,126) | (119,712) | (72,965) | (46,361) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.